STERIS /$STE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About STERIS
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
- Ticker
- $STE
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 17,937
- Headquarters
- Mentor, United States
- Website
- www.steris.com
STERIS Metrics
BasicAdvanced
$22B
27.07
$8.18
0.91
$2.58
1.25%
Price and volume
Market cap
$22B
Beta
0.91
52-week high
$269.44
52-week low
$195.14
Average daily volume
705K
Dividend rate
$2.58
Financial strength
Current ratio
1.906
Quick ratio
1.165
Long term debt to equity
0.244
Total debt to equity
0.262
Dividend payout ratio (TTM)
30.68%
Interest coverage (TTM)
18.97%
Profitability
EBITDA (TTM)
1,640.5
Gross margin (TTM)
44.42%
Net profit margin (TTM)
13.33%
Operating margin (TTM)
19.04%
Effective tax rate (TTM)
25.79%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
6.80%
Return on equity (TTM)
11.39%
Valuation
Price to earnings (TTM)
27.075
Price to revenue (TTM)
3.595
Price to book
2.99
Price to tangible book (TTM)
14.85
Price to free cash flow (TTM)
23.45
Free cash flow yield (TTM)
4.26%
Free cash flow per share (TTM)
9.445
Dividend yield (TTM)
1.16%
Forward dividend yield
1.25%
Growth
Revenue change (TTM)
8.37%
Earnings per share change (TTM)
25.28%
3-year revenue growth (CAGR)
9.78%
10-year revenue growth (CAGR)
9.52%
3-year earnings per share growth (CAGR)
89.85%
10-year earnings per share growth (CAGR)
16.73%
3-year dividend per share growth (CAGR)
10.26%
10-year dividend per share growth (CAGR)
9.68%
What the Analysts think about STERIS
Analyst ratings (Buy, Hold, Sell) for STERIS stock.
Analyst projections of the future price of STERIS stock.
Bulls say / Bears say
Fiscal Q1 2027 revenue rose 7% (6% organically); Healthcare services and consumables grew 10% and 9%, while Life Sciences revenue advanced 9%. Growth across these recurring lines supports the case for steady demand. (STERIS)
The announced $2.1 billion Xodus deal adds operating-room consumables, and Xodus is expected to generate $245 million in sales this year. Analysts cited by MedTech Dive see its high-growth, high-margin products as a potential earnings boost. (MedTech Dive)
STERIS is adding capacity where it says customer demand is accelerating: a second X-ray line in Venlo and an expanded Brooklyn Park laboratory that doubled testing capacity. These investments give its sterilisation and testing services more room to grow. (STERIS AST, STERIS AST)
AST organic growth was 5% in Q1, but capital-equipment revenue fell 13% and its operating margin narrowed to 48.0% from 48.6%. Higher depreciation and labour costs partly offset pricing, leaving this high-margin segment exposed if customer activity stays soft. (SEC)
AST faces environmental and regulatory risks from ethylene oxide and cobalt-60 sterilisation, while STERIS reports limited suppliers for key inputs including those materials. New restrictions or a supply interruption could disrupt operations or raise costs. (Fitch Ratings, SEC)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
STERIS Financial Performance
Revenues and expenses
STERIS Earnings Performance
Company profitability
Upcoming events
No upcoming events
STERIS News
AllArticlesVideos
Funds containing STERIS
AllUSDEURGBP
Fund name | Fund size | $STE weighting |
|---|---|---|
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 1.13% |
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 1.13% |
SPDR S&P US Dividend Aristocrats€SPYD | $3.8B | 0.55% |
SPDR S&P US Dividend Aristocrats£USDV | $3.8B | 0.55% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 0.40% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.